Skip to Content

BNY Mellon Developed Markets RE Scs - A DRLAX Fund Analysis

| Medalist Rating as of | See BNY Mellon Investment Hub

Morningstar’s Analysis DRLAX

Will DRLAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Strength in BNY Mellon Developed Markets RE Scs-A's People Pillar is partially offset by an Average Process Pillar rating, leading to a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor